Cuffe, M., Califf, R., Adams, K., Benza, R., Bourge, R., Colucci, W., … Hennersdorf, M. G. (2002). Intravenous milrinone is no better than standard therapy for people admitted with acute exacerbation of chronic heart failure. Evidence-Based Cardiovascular Medicine, 6(4), 154–155. https://doi.org/10.1054/ebcm.2002.0490

Cuffe, M., R. Califf, K. Adams, R. Benza, R. Bourge, W. Colucci, B. Massie, et al. “Intravenous milrinone is no better than standard therapy for people admitted with acute exacerbation of chronic heart failure.” Evidence-Based Cardiovascular Medicine 6, no. 4 (January 1, 2002): 154–55. https://doi.org/10.1054/ebcm.2002.0490.

Cuffe M, Califf R, Adams K, Benza R, Bourge R, Colucci W, et al. Intravenous milrinone is no better than standard therapy for people admitted with acute exacerbation of chronic heart failure. Evidence-based Cardiovascular Medicine. 2002 Jan 1;6(4):154–5.

Cuffe, M., et al. “Intravenous milrinone is no better than standard therapy for people admitted with acute exacerbation of chronic heart failure.” Evidence-Based Cardiovascular Medicine, vol. 6, no. 4, Jan. 2002, pp. 154–55. Scopus, doi:10.1054/ebcm.2002.0490.

Cuffe M, Califf R, Adams K, Benza R, Bourge R, Colucci W, Massie B, O’Connor C, Pina I, Quigg R, Silver M, Gheorghiade M, Hennersdorf MG. Intravenous milrinone is no better than standard therapy for people admitted with acute exacerbation of chronic heart failure. Evidence-based Cardiovascular Medicine. 2002 Jan 1;6(4):154–155.